Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Doan's Ads Superiority Claims "Material" To Consumers, Court Says

This article was originally published in The Tan Sheet

Executive Summary

Advertising for Novartis Consumer Health's Doan's Pills as a back pain treatment made implied, deceptive claims of superiority that were material to consumers' purchasing decisions, a federal appeals court says.

You may also be interested in...



Doan's pills

Analgesic bearing FTC-mandated corrective statement reaching stores now. In July 1999, the commission directed Novartis Consumer Health to include on all packaging for five years the statement: "Although Doan's is an effective pain reliever, there is no evidence that Doan's is more effective than other pain relievers for back pain." Novartis began shipping the new packaging Sept. 18 after an appeals court upheld the FTC order (1"The Tan Sheet" Aug. 28, p. 4)

Doan's pills

Analgesic bearing FTC-mandated corrective statement reaching stores now. In July 1999, the commission directed Novartis Consumer Health to include on all packaging for five years the statement: "Although Doan's is an effective pain reliever, there is no evidence that Doan's is more effective than other pain relievers for back pain." Novartis began shipping the new packaging Sept. 18 after an appeals court upheld the FTC order (1"The Tan Sheet" Aug. 28, p. 4)

Doan's pills

Analgesic bearing FTC-mandated corrective statement reaching stores now. In July 1999, the commission directed Novartis Consumer Health to include on all packaging for five years the statement: "Although Doan's is an effective pain reliever, there is no evidence that Doan's is more effective than other pain relievers for back pain." Novartis began shipping the new packaging Sept. 18 after an appeals court upheld the FTC order (1"The Tan Sheet" Aug. 28, p. 4)

Related Content

Topics

UsernamePublicRestriction

Register

PS091596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel